Call for Abstracts

2020 UHMS Evidence Review for HBO2 Treatment of COVID-19 Webinar

Saturday, June 20
11am - 5pm ET

DEADLINE FOR SUBMISSION: SUNDAY, MAY 24, MIDNIGHT ET


UHMS will be hosting a webinar on Evidence Review for HBO2 Treatment of COVID-19 on June 20, 2020 from 11am-5pm ET.  Click here to register for the free webinar. 

On behalf of the Undersea and Hyperbaric Medical Society, the UHMS Scientific Program Committee is pleased to announce the call for abstract submissions for Evidence Review for HBO2 Treatment of COVID-19.

For your convenience, the formatting and submission guidelines have been reprinted in the below section entitled "Abstract Formatting Guidelines."  Abstracts should be submitted via the UHMS website at www.uhms.org.  For those unable to access the UHMS website or having difficulty with the online submission format, additional assistance with the submission process can be obtained by contacting the UHMS home office.  Authors should ensure that all submission requirements are met, as incomplete submissions may be returned for modification or declined. Due to issues related to late submissions last year, this year's deadline for submission is May 24, 2020.  Acknowledgment of receipt will be provided promptly. 

TERMS AND CONDITIONS:

Abstract acceptance is at the full discretion of the UHMS Scientific Program Committee.  Also at the discretion of the UHMS Scientific Program Committee, presenters may be invited to present their abstract orally for the webinar to be held June 20, 2020 between the hours of 11am-5pm.

ABSTRACT USE PERMISSIONS AND RIGHTS:

All abstracts submissions for presentation at the UHMS Evidence Review HBO2 Treatment of COVID-19 webinar constitutes consent by the author(s) for the UHMS to use the materials submitted in whole or part as it sees fit.  All abstracts and oral presentations (including PowerPoint slides) accepted by the UHMS Scientific Program Committee for presentation at the UHMS HBO2 treatment of COVID-19 webinar may be subsequently used and/or published by the Society in various electronic media at the discretion of the UHMS.  Once accepted, no abstract or oral presentation may be withdrawn or excluded from being subject to this agreement.

DEADLINES:

  • REGULAR ABSTRACT SUBMISSION: SUNDAY, MAY 24, 2020; MIDNIGHT ET
  • NOTIFICATION OF ACCEPTANCE by ASM Program Committee: FRIDAY, MAY 29.
  • UPDATES WILL BE ACCEPTED UNTIL: SUNDAY, JUNE 7, 2020; MIDNIGHT ET

 ABSTRACT FORMATTING GUIDELINES:

LANGUAGE: All abstracts are to be written in English. The Scientific Program Committee reserves the right to alter abstracts where the English structure makes comprehension difficult.

ABSTRACT BODY FORMATPlease note that the abstract format described below must be followed strictly or it will not be considered for this meeting.

  • Must be 300 words or less, exclusive of title, author(s) names, and institutional affiliation(s). See examples at end of this document.
  • All submissions should be done through the UHMS online portal.
  • Only text and text tables will be accepted. No references, graphs or images may be submitted.
  • Contents should include the following sections and please use these exact terms for uniformity:
    • Introduction / Background
    • Materials and Methods
    • Results
    • Summary / Conclusions
  • Case Reports should include the following sections and please use these exact terms for uniformity
    • Case Description
    • Intervention
    • Outcome
    • Discussion
  • One question / Must be specific to your abstract/final poster presentation (The Q/A will be used for Evaluation of the participants for CME/Maintenance of Certification Credits (MOC) at the UHMS Online CME Portal). 

 TOPICS FOR PRESENTATION:

You will need to choose the category that best fits your abstract. The committee reserves the right to re-assign categories as needed to even out the program.

  • Pre-trial studies
  • Case Reports
  • Case series
  • Registry
  • Comparison studies
  • RCTs

If you would like some additional background about writing abstracts, we have found a very good source at the website of the American College of Physicians: https://www.acponline.org/membership/residents/competitions-awards/abstracts/preparing/vignette.  There you will find suggestions on determining whether your idea merits and abstract presentation by posing questions such as: Is this experience useful? Did we learn something from it? Does it cover an unusual aspect of an illness or suggest a novel method of treatment?  There's much more included in the ACP link to help you compose your abstract within the parameters of introduction/background, materials/methods, results and summary/conclusions.

Remember to take your time in writing your abstract; then take a day off. Share it with your colleagues. Often you will receive good suggestions in refining your presentation. When you come back to draft your final version, you will have a fresh perspective.



SAMPLE ABSTRACT 1:

Characteristics of the headache associated with acute carbon monoxide poisoning
Hampson NB, Hampson LA
email@email.com

Introduction / Background:  Headache is the most commonly reported symptom in acute carbon monoxide (CO) poisoning.  It is often described as throbbing and diffuse, however, a systematic characterization of CO-associated headache has never been published.  This study examines the characteristics of CO-associated headache to determine whether any typical pattern exists which might prove useful in the diagnosis of CO exposure.

Materials and Methods: 
Patients referred for hyperbaric oxygen (HBO2) treatment of acute CO poisoning were asked whether headache was part of their symptom complex.  When present, specific details about the nature of the headache were collected from 100 consecutive patients through use of a standardized questionnaire.

Results: 
Information on acute CO-associated headache was collected from 34 female and 66 male patients with mean carboxyhemoglobin (COHb) 21.3+9.3%.  The most common sources of CO were motor vehicles (31), forklifts (23), or furnaces (11).  Poisonings were accidental in 81%.  The most common location for pain was frontal (66%), although more than one location was involved in 58%.  Nature of the pain at any time during its course was dull in 72% and sharp in 36%.   Headache was throbbing in 41%.  Pain was continuous in 74% and intermittent in 16%.   Peak intensity of pain did not correlate with COHb level.   Symptoms commonly associated with headache included dizziness, lightheadedness, weakness, and nausea.  Headache improved prior to HBO2 treatment in 72%, resolving entirely in 21%.  Of those with residual headache, pain improved with HBO2 in 97%, resolving entirely in 44%.

Summary / Conclusions: 
The headache accompanying acute CO poisoning is extremely variable in nature.   "Classic" throbbing diffuse headaches were rarely described by patients.  There are no patterns which can be considered characteristic to aid in the diagnosis of CO-induced headache.  Similarly, no trait was identified which might allow elimination of CO poisoning from the differential diagnosis of headache.

Suggested category: HBO Clinical
Authorizations: a) Y    b) Y
Financial disclosure: a) N    b) N    c) nil   d) N
CV: Brief


SAMPLE ABSTRACT 2: 

Serum S-100b as a marker of neurological events in goats following direct decompression in a simulated disabled submarine scenario 
Jurd KM, Parmar K, Seddon FM,  Loveman GAM, Blogg SL, Thacker JC, Stansfield MRD, White MG, Hunt BJ. 
email@email.com

Introducation / Background:
S100b is a glial protein used as a marker of cerebral damage in a number of clinical situations. Neurological decompression illness (DCI) is a major risk following rapid decompression to the surface in a disabled submarine (DISSUB) scenario if recompression facilities are unavailable. The aim of this study was to investigate levels of S-100b in goats under simulated DISSUB conditions where neurological DCI may occur.

Materials and Methods:
Adult female or castrated male goats (35-75 kg) underwent dry chamber air saturation between 55 and 85 fsw for 24 h followed by rapid decompression at 0.9 bar/min (n=37). Gross neurological involvement was determined by clinical assessment and post mortem examination.  Venous blood samples were taken pre-dive and at 5, 30, 60, 90, 120, 180 and 240 mins post surfacing.  S-100b was measured in serial samples by immunoluminometric assay.

Results: 
Neurological DCI was mainly evident in the goats which had undergone the deeper profiles.  A greater percentage of animals undergoing these deeper profiles also had increased levels of S-100b compared to pre-dive values. The percentage of animals at each depth with raised S100b increased from 0% at 55 fsw to 100% at 85 fsw.  Increases in levels of S100b were evident at 5 or 30 mins in most cases, with levels continuing to rise for at least 120 mins.

Summary / Conclusions: This study demonstrates that S100b is raised in goats following "rapid decompression" from air saturation at depths below 55 fsw.  S100b may be useful as a marker of cerebral events in neurological DCI. 

BritishCrown Copyright 2001
Published with the permission of DERA on behalf of the controller HMSO

Suggested category: Decompression IllnessAuthorizations: a) Y    b) Y
Financial disclosure*: a) Y,   b) Y,   Manufacturer ILA Co. (Immunoluminometric Assay).
Lead author is owner of company.  
NOTE: *fictitious, created as an example only,  c) Y, mm/dd/yyyy
CV: brief


SAMPLE ABSTRACT 3: CASE REPORT:

Hyperbaric oxygen treatment of decompression sickness: case reports from Louisiana State University Undersea and Hyperbaric Medicine Fellowship Program
Shamitko G, Hickey B, Pavelites J, Murphy-Lavoie H, LeGros TL
LSU Department of Hyperbaric Medicine, University Medical Center and West Jefferson Medical Center
email@email.com

Case Description:
The risk of decompression illness (DCI) is sometimes minimized by recreational diving groups. Decompression illness is an omnipresent concern for those subjected to higher-than-atmospheric pressures. This includes both recreational and commercial underwater diving, as well as those receiving hyperbaric oxygen (HBO2) therapy for wound healing. Symptoms can range from minor skin or joint findings to severe paralysis, spinal cord injury, pulmonary edema, and death. The authors present a series of five case reports outlining recent decompression injury experiences treated at the LSU post-graduate medical training program in Undersea and Hyperbaric Medicine. 

Intervention:
Five emergent decompression injuries treated at WJMC were summarized by treating LSU UHM Fellows and reviewed by attending physicians. 

Outcome:
Five cases of decompression illness are presented, each with varying degrees of neurologic disability.

Cases 1 and 2 were injured recreational divers in Mexico, who were diving “safe profiles” and sustained significant paralysis and mental status changes. After delayed presentation for treatment at West Jefferson Medical Center these injuries resolved. 

Case 3 highlights a potential iatrogenic injury involving unilateral blindness during routine wound treatment with hyperbaric oxygen therapy. Blindness resolved after continued therapy with hyperbaric oxygen therapy. 

Case 4 is a recreational diver from Zanzibar with a previously unknown pulmonary bleb who was injured during a routine dive, with delayed resolution after treatment. 

Case 5 is a local “hell diver” spear fisherman, who routinely practices unsafe diving profiles. He was injured after exceeding decompression limits but recovered fully after prompt treatment.

Discussion:
The wide variety of serious decompression illness presented here does not support the widely advertised assertion that “diving is as safe as bowling.” Four of five cases in this presentation were “undeserved” (unexplained) hits and underscores the need for better preventive measures and continued research into DCI.